LIFECORE BIOMEDICAL, INC. (LFCR) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
43/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 3 wins, 9 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinLFCR / S&P 41.13% / 15.20% |
LoseLFCR / S&P LFCR unavailable / 15.00% |
LoseLFCR / S&P LFCR unavailable / 50.40% |
| 2026-Q10/3 |
LoseLFCR / S&P -54.52% / -4.33% |
LoseLFCR / S&P LFCR unavailable / 11.30% |
LoseLFCR / S&P LFCR unavailable / 27.70% |
| 2025-Q41/3 |
WinLFCR / S&P 11.14% / 2.65% |
LoseLFCR / S&P LFCR unavailable / 9.00% |
LoseLFCR / S&P LFCR unavailable / 13.40% |
| 2025-Q31/3 |
LoseLFCR / S&P -9.36% / 8.12% |
WinLFCR / S&P 5.31% / 4.61% |
LoseLFCR / S&P -1233.33% / 13.45% |
| 2025-Q21/3 |
WinLFCR / S&P 15.34% / 10.94% |
LoseLFCR / S&P 0.47% / 4.83% |
LoseLFCR / S&P -566.67% / 10.63% |
| 2025-Q12/3 |
LoseLFCR / S&P -5.25% / -4.27% |
WinLFCR / S&P 7.23% / 4.98% |
WinLFCR / S&P 65.48% / 10.57% |
| 2024-Q42/3 |
WinLFCR / S&P 50.71% / 2.41% |
WinLFCR / S&P 16.47% / 5.25% |
LoseLFCR / S&P -77.64% / 6.15% |
| 2024-Q31/3 |
LoseLFCR / S&P -3.90% / 5.89% |
WinLFCR / S&P 23.42% / 5.89% |
LoseLFCR / S&P -102.74% / 6.11% |
| 2024-Q21/3 |
LoseLFCR / S&P -3.39% / 4.28% |
WinLFCR / S&P 24.20% / 5.38% |
LoseLFCR / S&P -108.18% / 5.12% |
| 2024-Q11/3 |
LoseLFCR / S&P -14.22% / 10.56% |
WinLFCR / S&P 30.31% / 5.71% |
LoseLFCR / S&P -78.35% / 5.59% |
| 2023-Q41/3 |
LoseLFCR / S&P -18.01% / 11.69% |
WinLFCR / S&P 7.91% / 6.81% |
LoseLFCR / S&P -21.41% / 7.78% |
| 2023-Q30/3 |
LoseLFCR / S&P -21.92% / -3.27% |
LoseLFCR / S&P -17.21% / 7.52% |
LoseLFCR / S&P -18.00% / -5.03% |
| 2023-Q21/3 |
WinLFCR / S&P 155.82% / 8.74% |
LoseLFCR / S&P -28.09% / 9.50% |
LoseLFCR / S&P -16.46% / -8.57% |
| 2023-Q11/3 |
LoseLFCR / S&P -41.67% / 7.50% |
LoseLFCR / S&P -3.59% / 10.77% |
WinLFCR / S&P 83.89% / -15.69% |
| 2022-Q41/3 |
LoseLFCR / S&P -27.11% / 7.56% |
LoseLFCR / S&P 0.09% / 11.88% |
WinLFCR / S&P 69.19% / -17.99% |
| 2022-Q31/3 |
LoseLFCR / S&P -10.83% / -4.88% |
LoseLFCR / S&P -34.35% / 13.47% |
WinLFCR / S&P 300.00% / -1.41% |
| 2022-Q22/3 |
WinLFCR / S&P -13.90% / -16.10% |
LoseLFCR / S&P -49.69% / 13.71% |
WinLFCR / S&P 272.64% / 11.04% |
| 2022-Q12/3 |
WinLFCR / S&P 4.32% / -4.60% |
WinLFCR / S&P 160.95% / 15.97% |
LoseLFCR / S&P 37.01% / 42.23% |
| 2021-Q41/3 |
WinLFCR / S&P 20.39% / 11.03% |
LoseLFCR / S&P -28.41% / 15.00% |
LoseLFCR / S&P 6.32% / 96.40% |
| 2021-Q31/3 |
LoseLFCR / S&P -18.04% / 0.58% |
WinLFCR / S&P 21.96% / 10.77% |
LoseLFCR / S&P -34.21% / 69.42% |
| 2021-Q21/3 |
LoseLFCR / S&P 6.13% / 8.55% |
WinLFCR / S&P 78.35% / 6.58% |
LoseLFCR / S&P -18.46% / 51.81% |
| 2021-Q11/3 |
LoseLFCR / S&P -2.30% / 6.17% |
LoseLFCR / S&P -93.69% / -1.06% |
WinLFCR / S&P 94.94% / 7.39% |
| 2020-Q41/3 |
LoseLFCR / S&P 11.63% / 12.15% |
LoseLFCR / S&P -75.36% / -3.72% |
WinLFCR / S&P 383.33% / -33.42% |
| 2020-Q32/3 |
WinLFCR / S&P 22.11% / 8.93% |
LoseLFCR / S&P -72.53% / -2.04% |
WinLFCR / S&P 913.33% / -27.10% |
| 2020-Q20/3 |
LoseLFCR / S&P -8.40% / 20.54% |
LoseLFCR / S&P -71.29% / -0.46% |
LoseLFCR / S&P -6600.00% / -27.11% |
| 2020-Q11/3 |
LoseLFCR / S&P -23.17% / -19.60% |
WinLFCR / S&P 7.54% / 3.47% |
LoseLFCR / S&P -416.00% / -14.75% |
| 2019-Q41/3 |
LoseLFCR / S&P 4.05% / 9.07% |
WinLFCR / S&P 10.17% / 5.36% |
LoseLFCR / S&P -146.15% / 2.99% |
| 2019-Q32/3 |
WinLFCR / S&P 16.01% / 1.70% |
WinLFCR / S&P 7.22% / 5.02% |
LoseLFCR / S&P -118.29% / 0.21% |
| 2019-Q20/3 |
LoseLFCR / S&P -23.70% / 4.30% |
LoseLFCR / S&P 6.36% / 6.64% |
LoseLFCR / S&P -97.75% / 8.65% |
| 2019-Q11/3 |
LoseLFCR / S&P 3.72% / 13.65% |
WinLFCR / S&P 21.82% / 8.12% |
LoseLFCR / S&P -67.11% / 14.29% |
| 2018-Q42/3 |
LoseLFCR / S&P -17.78% / -13.52% |
WinLFCR / S&P 21.71% / 9.05% |
WinLFCR / S&P 143.75% / 18.23% |
| 2018-Q32/3 |
LoseLFCR / S&P -3.36% / 7.71% |
WinLFCR / S&P 17.64% / 10.21% |
WinLFCR / S&P 134.29% / 19.06% |
| 2018-Q23/3 |
WinLFCR / S&P 14.18% / 3.43% |
WinLFCR / S&P 11.59% / 9.03% |
WinLFCR / S&P 128.21% / 14.46% |
| 2018-Q12/3 |
WinLFCR / S&P 3.57% / -0.76% |
LoseLFCR / S&P -17.04% / 7.68% |
WinLFCR / S&P 58.33% / 12.46% |
| 2017-Q40/3 |
LoseLFCR / S&P -2.70% / 6.64% |
LoseLFCR / S&P -17.58% / 7.03% |
LoseLFCR / S&P -174.42% / 13.82% |
| 2017-Q30/3 |
LoseLFCR / S&P -12.79% / 4.48% |
LoseLFCR / S&P -15.79% / 5.68% |
LoseLFCR / S&P -185.37% / 17.57% |
| 2017-Q21/3 |
WinLFCR / S&P 23.75% / 3.09% |
LoseLFCR / S&P -13.18% / 4.83% |
LoseLFCR / S&P -192.86% / 17.74% |
| 2017-Q10/3 |
LoseLFCR / S&P -13.04% / 6.07% |
LoseLFCR / S&P -0.02% / 3.67% |
LoseLFCR / S&P -209.09% / 13.32% |
| 2016-Q40/3 |
LoseLFCR / S&P 2.91% / 3.82% |
LoseLFCR / S&P -2.77% / 2.09% |
LoseLFCR / S&P -189.58% / 7.05% |
| 2016-Q31/3 |
WinLFCR / S&P 24.63% / 3.85% |
LoseLFCR / S&P -0.53% / 0.20% |
LoseLFCR / S&P -177.36% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | LFCR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -40.34% | 20.78% |
| Annualized return | -40.34% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | LFCR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -56.68% | 83.14% |
| Annualized return | -15.41% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | LFCR total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -64.59% | 319.30% |
| Annualized return | -9.86% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |